What is DeepLife?
DeepLife is at the forefront of cellular engineering, developing novel solutions to combat diseases stemming from cellular perturbations. Leveraging state-of-the-art multi-omics data, machine learning, and systems engineering, the company aims to identify and rectify the molecular triggers that lead to pathological cellular states. This innovative methodology represents a significant advancement over traditional iterative reconstruction of cell mechanisms, offering a more direct path to restoring cellular health.
How much funding has DeepLife raised?
DeepLife has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2024): $10M with participation from Relyens en France, Groupe Prunay, Beiersdorf, and YZR Capital
Key Investors in DeepLife
Relyens en France
Relyens en France is a notable entity in the insurance sector, suggesting a strategic interest in companies that mitigate health-related risks or offer innovative healthcare solutions.
Groupe Prunay
Groupe Prunay, with its diversified portfolio including venture capital, indicates a focus on supporting high-growth potential businesses, aligning with DeepLife's innovative technological trajectory.
Beiersdorf
Beiersdorf, a global leader in skincare, may see strategic value in DeepLife's cellular engineering capabilities for advancements in dermatological health and regenerative medicine.
What's next for DeepLife?
With this substantial enterprise-level backing, DeepLife is poised to accelerate its research and development initiatives. The strategic investment will likely fuel the expansion of its technological platform, enabling deeper insights into complex cellular interactions and the development of targeted therapeutic interventions. The company's focus on data-driven biological discovery positions it for significant growth and impact in the biotechnology and healthcare sectors.
See full DeepLife company page
